Healthcare / Medical DevicesKOSDAQ
$22450.00
+450.00 (+2.05%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 26% · confianza 25%
FCF escenarios
weak_data · normalized FCF $-14.0B · quality 65.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
11/100
F
Piotroski
4/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
8/100
SEC 0%
Sin guardar todavía.
Market Cap
$248.2B
P/E
N/A
•EV/EBITDA
N/A
•ROE
-55.4%
↓Gross Margin
59.7%
↑Debt/Equity
0.63
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2024–2025 · 1 años de histórico normalizado
Revenue CAGR
+27.3%
FCF CAGR
—
FCF margin
-87.9%
FCF / Net income
1.55x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $20.53B · net income $-11.67B · FCF $-18.05B
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 |
|---|---|---|---|
| Income Statement | |||
| Revenue | $20.53B | $20.53B | $16.12B |
| Net Income | $-11.67B | $-11.67B | $-32.66B |
| EBITDA | $-9.91B | $-9.91B | $-27.96B |
| EPS | -1190.00 | -1190.00 | -6799.00 |
| Gross Margin | 59.7% | 59.7% | 47.5% |
| Operating Margin | -53.8% | -53.8% | -56.9% |
| Net Margin | -56.8% | -56.8% | -202.6% |
| Balance Sheet | |||
| Debt/Equity | 0.63 | 0.63 | 3.54 |
| Current Ratio | 1.35 | 1.35 | — |
| Cash Flow | |||
| Free Cash Flow | $-18.05B | $-18.05B | $-9.86B |
| Returns | |||
| ROE | -55.4% | -55.4% | -846.8% |
| Valuation | |||
| P/B | 10.46 | 10.46 | — |
| Growth & Yield | |||
| Revenue Growth | 27.3% | 27.3% | — |
| EPS Growth | 82.5% | 82.5% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+99.4%
Start / end P/E
n/dx → n/dx
EPS bridge
-6799.00 → -1190.00
Residual
+99.4%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.